BTIG Research Issues Positive Forecast for Bicara Therapeutics (NASDAQ:BCAX) Stock Price

Bicara Therapeutics (NASDAQ:BCAX) had its price target boosted by investment analysts at BTIG Research from $28.00 to $39.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s target price points to a potential upside of 64.14% from the stock’s current price.

Other equities research analysts have also recently issued reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. The Goldman Sachs Group boosted their price objective on shares of Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. Guggenheim assumed coverage on shares of Bicara Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $42.00 target price on the stock. Finally, Wall Street Zen raised shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.45.

Bicara Therapeutics Stock Performance

Shares of NASDAQ:BCAX opened at $23.76 on Wednesday. The business’s fifty day moving average price is $25.90 and its two-hundred day moving average price is $21.69. The stock has a market cap of $1.56 billion, a PE ratio of -8.55 and a beta of -0.75. Bicara Therapeutics has a one year low of $9.67 and a one year high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.82). As a group, equities research analysts predict that Bicara Therapeutics will post -3.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Bicara Therapeutics news, CEO Claire Mazumdar sold 10,000 shares of the business’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $28.42, for a total transaction of $284,200.00. Following the completion of the sale, the chief executive officer owned 362,152 shares of the company’s stock, valued at approximately $10,292,359.84. The trade was a 2.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 28,000 shares of the company’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $28.85, for a total value of $807,800.00. Following the sale, the chief financial officer owned 129,855 shares of the company’s stock, valued at $3,746,316.75. This represents a 17.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 88,450 shares of company stock valued at $2,366,675. 13.80% of the stock is currently owned by company insiders.

Institutional Trading of Bicara Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Siren L.L.C. raised its holdings in Bicara Therapeutics by 11.2% in the first quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock valued at $115,421,000 after buying an additional 586,001 shares during the period. Vestal Point Capital LP increased its position in shares of Bicara Therapeutics by 2.0% in the third quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock worth $80,529,000 after acquiring an additional 100,000 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Bicara Therapeutics in the second quarter worth $114,250,000. Janus Henderson Group PLC increased its position in shares of Bicara Therapeutics by 26.2% in the first quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock worth $66,350,000 after acquiring an additional 692,933 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. raised its stake in shares of Bicara Therapeutics by 596.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after acquiring an additional 2,771,868 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.